📰 Aadi Bioscience News
Page 10 - Aadi Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Aadi Bioscience. Real-time updates on events, politics, business and more.
March 27, 2023
Los Angeles-based biopharmaceuticals company Aadi Bioscience announced this morning that it has added Mohammad Hirmand, M.D., to its board of directors. Hirmand was most recently Executive Vice President and C
March 26, 2023
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...
March 26, 2023
LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway...
March 3, 2023
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined...
February 22, 2023
/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision...
February 2, 2023
Cell-free DNA concentration is significantly increased in the first 2 weeks after surgery but these higher levels do not seem to interfere with monitoring of circulating tumor DNA for prognostic purposes.
November 10, 2022
Item 2.02. Results of Operations and Financial Condition. On November 9, 2022, Aadi Bioscience, Inc. issued a press release announcing its financial results for the fiscal quarter ended September... | November 9, 2022
November 9, 2022
LOS ANGELES, Nov. 8, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. , a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR... | November 9, 2022
November 9, 2022
GuruFocus Article or News written by PRNewswire and the topic is about:
November 8, 2022
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of...